Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab

Neurocognitive decline is a frequent adverse effect of glioblastoma. Antitumor therapies that are efficacious, as measured by traditional endpoints such as objective response (OR) and progression-free survival (PFS), and have beneficial effects on neurocognitive function (NCF) are of clinical benefi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Wefel, Jeffrey S., Cloughesy, Timothy, Zazzali, James L., Zheng, Maoxia, Prados, Michael, Wen, Patrick Y., Mikkelsen, Tom, Schiff, David, Abrey, Lauren E., Yung, W.K. Alfred, Paleologos, Nina, Nicholas, Martin K., Jensen, Randy, Vredenburgh, James, Das, Asha, Friedman, Henry S.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2011
Assuntos:
Clinical Investigations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3107095/
https://ncbi.nlm.nih.gov/pubmed/21558074
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nor024
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados